Clinical Immunogenetics Laboratory Associate Director

Overview

Fred Hutchinson Cancer Center is an independent, nonprofit organization providing adult cancer treatment and groundbreaking research focused on cancer and infectious diseases. Based in Seattle, Fred Hutch is the only National Cancer Institute-designated cancer center in Washington.

With a track record of global leadership in bone marrow transplantation, HIV/AIDS prevention, immunotherapy and COVID-19 vaccines, Fred Hutch has earned a reputation as one of the world's leading cancer, infectious disease and biomedical research centers. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services, and network affiliations with hospitals in five states.

Together, our fully integrated research and clinical care teams seek to discover new cures to the world's deadliest diseases and make life beyond cancer a reality.

At Fred Hutch we value collaboration, compassion, determination, excellence, innovation, integrity and respect. Our mission is directly tied to the humanity, dignity and inherent value of each employee, patient, community member and supporter. Our commitment to learning across our differences and similarities make us stronger. We seek employees who bring different and innovative ways of seeing the world and solving problems.

With the Laboratory Director, is responsible for the scientific and technical oversight of the Clinical Immunogenetics Laboratory (CIL), which is specialized in histocompatibility assessment of patient and donor candidates before hematopoietic cell transplantation (HCT), post-HCT monitoring, as well as non-transplant related testing.

The Associate Director will provide expertise, review and approve the design, development and implementation of projects and processes within the CIL as delegated by the CIL Laboratory Director. This will include certain limited procedures and practices, along with supporting standard operating procedures (SOPs) validations and qualifications.

In collaboration with CIL Laboratory Director and the management team, the Associate Director will provide support for program planning, quality assurance, performance improvement, staff development, and identification of capital needs.

• Regularly and directly participate in CIL clinical service/patient care activities. Respond to and address clinical care concerns regarding safety standards and practice issues that impact patient care. Oversee supervisory and technical steps in the performance of clinical duties; resolve technical problems.
• Review cross match, antibody, HLA typing, engraftment test results, PT results and world book search results and sign out clinical reports as needed.
• Ensure that testing systems and methodologies developed and performed for all Histocompatibility and Immunogenetic testing methods meet applicable quality requirements under ASHI standards and CLIA/CAP guidelines.
• Work in collaboration with the Laboratory Director, QA Senior Manager and lab management team to provide cross-departmental oversight and guidance for quality and safety.
• Under CIL Laboratory Director's guidance, provide technical and scientific oversight of CIL including development and implementation of new assays, procedures and practices, validations, qualifications, investigations, and planned and unplanned variances. Serve as an approver to controlled documents in CIL, as delegated by the CIL Laboratory Director.
• Ensure standard operating procedures (SOPs) are written and consistent with the methods performed in the laboratory and are adequate to determine the reliability, accuracy, precision, and other relevant characteristics of test methods. Ensure the establishment and maintenance of acceptable levels of analytical performance per SOP for each testing system and method. Ensure all necessary remedial actions taken are documented whenever significant deviations occur from the laboratory's established performance standards.
• Provide consultation to physicians and investigators in selecting safe donors for highly sensitized patients and monitoring post-HCT engraftment as needed.
• Stay up to date with the research…